Cargando…
Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents
Cancer is one of the top leading causes of death worldwide. It is a heterogenous disease characterized by unregulated cell proliferation and invasiveness of abnormal cells. For the treatment of cancer, natural products have been widely used as a source of therapeutic ingredients since ancient times....
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572494/ https://www.ncbi.nlm.nih.gov/pubmed/36235168 http://dx.doi.org/10.3390/molecules27196632 |
_version_ | 1784810628974641152 |
---|---|
author | Sflakidou, Eleni Leonidis, George Foroglou, Eirini Siokatas, Christos Sarli, Vasiliki |
author_facet | Sflakidou, Eleni Leonidis, George Foroglou, Eirini Siokatas, Christos Sarli, Vasiliki |
author_sort | Sflakidou, Eleni |
collection | PubMed |
description | Cancer is one of the top leading causes of death worldwide. It is a heterogenous disease characterized by unregulated cell proliferation and invasiveness of abnormal cells. For the treatment of cancer, natural products have been widely used as a source of therapeutic ingredients since ancient times. Although natural compounds and their derivatives have demonstrated strong antitumor activity in many types of cancer, their poor pharmacokinetic properties, low cell selectivity, limited bioavailability and restricted efficacy against drug-resistant cancer cells hinder their wide clinical application. Conjugation of natural products with other bioactive molecules has given rise to a new field in drug discovery resulting to the development of novel, bifunctional and more potent drugs for cancer therapy to overcome the current drawbacks. This review discusses multiple categories of such bifunctional conjugates and highlights recent trends and advances in the development of natural product hybrids. Among them, ADCs, PDCs, ApDCs, PROTACs and AUTOTACs represent emerging therapeutic agents against cancer. |
format | Online Article Text |
id | pubmed-9572494 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95724942022-10-17 Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents Sflakidou, Eleni Leonidis, George Foroglou, Eirini Siokatas, Christos Sarli, Vasiliki Molecules Review Cancer is one of the top leading causes of death worldwide. It is a heterogenous disease characterized by unregulated cell proliferation and invasiveness of abnormal cells. For the treatment of cancer, natural products have been widely used as a source of therapeutic ingredients since ancient times. Although natural compounds and their derivatives have demonstrated strong antitumor activity in many types of cancer, their poor pharmacokinetic properties, low cell selectivity, limited bioavailability and restricted efficacy against drug-resistant cancer cells hinder their wide clinical application. Conjugation of natural products with other bioactive molecules has given rise to a new field in drug discovery resulting to the development of novel, bifunctional and more potent drugs for cancer therapy to overcome the current drawbacks. This review discusses multiple categories of such bifunctional conjugates and highlights recent trends and advances in the development of natural product hybrids. Among them, ADCs, PDCs, ApDCs, PROTACs and AUTOTACs represent emerging therapeutic agents against cancer. MDPI 2022-10-06 /pmc/articles/PMC9572494/ /pubmed/36235168 http://dx.doi.org/10.3390/molecules27196632 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Sflakidou, Eleni Leonidis, George Foroglou, Eirini Siokatas, Christos Sarli, Vasiliki Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents |
title | Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents |
title_full | Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents |
title_fullStr | Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents |
title_full_unstemmed | Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents |
title_short | Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents |
title_sort | recent advances in natural product-based hybrids as anti-cancer agents |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572494/ https://www.ncbi.nlm.nih.gov/pubmed/36235168 http://dx.doi.org/10.3390/molecules27196632 |
work_keys_str_mv | AT sflakidoueleni recentadvancesinnaturalproductbasedhybridsasanticanceragents AT leonidisgeorge recentadvancesinnaturalproductbasedhybridsasanticanceragents AT forogloueirini recentadvancesinnaturalproductbasedhybridsasanticanceragents AT siokataschristos recentadvancesinnaturalproductbasedhybridsasanticanceragents AT sarlivasiliki recentadvancesinnaturalproductbasedhybridsasanticanceragents |